Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial

Jong Wook Lee(The Catholic University of Korea Seoul St. Mary's Hospital), Yasuo Mori, David Beneitez Pastor(Vall d'Hebron Hospital Universitari), Deepak Jain, Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Natalia Kreiniz(Bnai Zion Medical Center), Gleb Filippov(Azienda Ospedaliera S.Giuseppe Moscati), Fiorenza Barraco(Hôpital Lyon Sud), Marcelo Capra, Jiřı́ Mayer(Masaryk University), Toshiyuki Kitano(Kyoto University), Anna Paola Iori(Sapienza University of Rome), Alexander Gural, Lindsay Mitchell(Monklands Hospital), Lee Ping Chew, Flore Sicre de Fontbrune(Assistance Publique – Hôpitaux de Paris), Tadao Ishida(Japanese Red Cross Medical Center), Ibrahim Ibrahim, Lily Wong Lee Lee(Queen Elizabeth Hospital), Stavroula Giannouli(National and Kapodistrian University of Athens), Édouard Forcade(Hôpital Cardiologique du Haut-Lévêque), Hiroshi Kosugi(Ogaki Municipal Hospital), Cossor Furha, Peng Liu(Alexion Pharmaceuticals (United States)), Jin Seok Kim(University of Ulsan), Carlos de Castro, Michel Michels Oliveira, Ataúlfo González-Fernández, Régis Peffault de la Tour(Université Paris Cité), Inés Hernández‐Rodríguez(Azienda Ospedaliera S.Giuseppe Moscati), Eros Di Bona(San Antonio College), Emilio Ojeda Gutierrez, Jun‐ichi Nishimura(The University of Osaka), Cynthia Carrillo Infante(Alexion Pharmaceuticals (United States)), Anna Gaya Valls
The Lancet Haematology
November 27, 2023
Cited by 88


Related Papers